Guido Grassi – författare

The second edition of this well-received book will offer both new insights into the intimate mechanisms of transition from hypertension to heart failure and clinical practice advice on the prevention and treatment of heart failure in hypertensive population. Heart failure is the result of the hypertension''s effects on the heart and it is a growing public health problem, as it affects  20-50% of the adult population in developed countries.

In this context the international scientific community is continuously struggling to develop better strategies in screening, diagnosing and treating hypertension and its deleterious effects. Thus, this field is continuously changing, with new important information being added constantly.   A part of the book dedicated to diagnostics, comprising a chapter on new perspectives on multimodality imaging and a special chapter on diastolic dysfunction. The arrhythmic complications of hypertensive heart disease are  discussed in two chapters on atrial fibrillation and ventricular arrhythmias respectively. Readers will also find new chapters regarding hypertension and heart failure in special populations such as cancer patients, young patients, pregnancy and patients with a history of SARS-CoV2 infection. 

This book addresses all aspects of white coat hypertension – the phenomenon of raised blood pressure in a medical setting yet not elsewhere – from its history to its pathophysiology, diagnosis and treatment. White coat hypertension is a common condition, accounting for 30–40% of the overall hypertensive population. While many studies have addressed this condition, controversy still exists over whether it causes an increased risk to sufferers and should be treated.

In the volume neurogenic and non-neurogenic mechanisms are discussed and the significance of various predictive factors, evaluated. The association of white coat hypertension with dysmetabolic risk factors, new-onset diabetes and other conditions is carefully reviewed. Further chapters consider the occurrence of asymptomatic organ damage and cardiovascular outcomes in affected patients and helpful guidance is also provided on the controversial issue of when to treat and when not to treat. White Coat Hypertension is based largely on work done during the past 30 years by renowned researchers working in Milan, who have made key contributions in improving knowledge of the condition and whose work is well known across the world.